drugset / Trial / NCT04422561

Prophylactic Ivermectin in COVID-19 Contacts

NCT04422561

Phase 2/3 Completed 340 enrolled Zagazig University
RandomizedSequentialOpen-labelPrevention

Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19

Timeline

Start
2020-05-31
Primary completion
2020-07-14
Completion
2020-07-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule

Indications